patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the … biotherapeutics tocilizumab, siltuximab and sarilumab. … support national patent offices and interested parties in developing countries with information that can serve as guidance for …